EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prescription Drugs in Pregnancy and Congenital Malformations: A Population‐Based Safety Screening Study

Anne Broe iD, Anton Pottegård iD, Trine Munk-Olsen iD, Jesper Hallas iD, Mette Bliddal iD, Irene Petersen iD, Per Damkier iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Anne Broe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Abnormalities, Drug-Induced, Prescription Drugs, Congenital Abnormalities. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Counseling women who are either pregnant or contemplating pregnancy on their use of prescribed drugs remains a major clinical challenge. Since the thalidomide tragedy in the 1960s, the use of drugs during pregnancy has been subject to widespread concern due to the potential for unwanted effects on the unborn child, notably major congenital malformations.

Objective

To examine the risk of major congenital malformations following first trimester exposure to all marketed prescription drugs in Denmark. Study Design This was a population‐based cohort study utilizing national health registries in Denmark. We studied all singleton livebirths in Denmark between January 1, 2004, and December 31, 2017, and we linked data from the National Danish Prescription Register, Birth Register, Patient Register, and Cause of Death Register. Using logistic regression analysis, we compared exposed liveborn to unexposed liveborn children while controlling for important confounders. The main outcome measure was major congenital malformations, and the secondary outcomes included organ‐specific major congenital malformations as defined by EUROCAT.

Results

Of 326 drugs with at least 5 livebirths with major congenital malformations, 31 were associated with an increased risk of major congenital malformations compared to unexposed livebirths (adjusted Odds Ratio [aOR] ≥ 2.0). Compared to livebirths of women who discontinued treatment prior to pregnancy, 17 drugs with an increased risk (aOR ≥ 2.0) were identified. Among 115 drugs prescribed to ≥ 1000 women during the first trimester, only insulins had aORs ≥ 2.0 for overall major congenital malformations. There were > 100 drugs with no increased risk of major congenital malformations.

Conclusions

Using a complete nationwide dataset, > 100 null‐associations between first‐trimester drug exposure and overall major congenital malformations were documented. This provides important insights and reassurance to support pregnant women and inform shared decision making. We confirm previously known teratogenic drugs and other potential teratogenic drugs, clopidogrel and liraglutide, were identified. These latter associations should be addressed in future studies using disease‐specific confounder control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abnormalities, Drug-InducedPrescription DrugsCongenital AbnormalitiesHumansFemalePregnancyDenmarkAdultRegistriesPregnancy Trimester, FirstCohort StudiesYoung Adult

Stichwörter der Autor:innen

congenital malformationsdrugspregnancy

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
  • IQVIA London, London, UK.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
  • Children and Adolescent Psychiatric Research Unit, Region of Southern Denmark, Odense, Denmark.
  • Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Anne Broe, Anton Pottegård, Trine Munk-Olsen, Jesper Hallas, Mette Bliddal, Irene Petersen, Per Damkier

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Broe, A., Pottegård, A., Munk-Olsen, T., Hallas, J., Bliddal, M., Petersen, I., & Damkier, P. (2025). Prescription Drugs in Pregnancy and Congenital Malformations: A Population‐Based Safety Screening Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70211

Vancouver

Broe A, Pottegård A, Munk-Olsen T, Hallas J, Bliddal M, Petersen I, et al. Prescription Drugs in Pregnancy and Congenital Malformations: A Population‐Based Safety Screening Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70211

BibTeX
@article{Broe2025,
  author = {Broe, Anne and Pottegård, Anton and Munk-Olsen, Trine and Hallas, Jesper and Bliddal, Mette and Petersen, Irene and Damkier, Per},
  title = {Prescription Drugs in Pregnancy and Congenital Malformations: A Population‐Based Safety Screening Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70211}
}
Kostenlos starten →